Pretreatment Prediction of Brain Tumors Response to Radiation Therapy Using High b-Value Diffusion-Weighted MRI  by Mardor, Yael et al.
Pretreatment Prediction of Brain Tumors Response to Radiation
Therapy Using High b-Value Diffusion-Weighted MRI1
Yael Mardor*,**, Yiftach Roth*,y, Aharon Ocherashvilli *, Roberto Spiegelmann z,§, Thomas Tichlerb,
Dianne Daniels*, Stephan E. Maier #, Ouzi Nissim z, Zvi Ram z,§, Jacob Baram§,b, Arie Orenstein*
and Raphael Pfeffer §,b
*Advanced Technology Center, Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52621, Israel; ySchool of
Physics and Astronomy, Tel-Aviv University, Tel-Aviv, Israel; zNeurosurgery Department, Sheba Medical Center,
Tel-Hashomer 52621, Israel; §Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; bOncology
Institute, Sheba Medical Center, Tel-Hashomer 52621, Israel; #Department of Radiology, Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA; **The Sheba Cancer Research Center,
Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52621, Israel
Abstract
Diffusion-weighted magnetic resonance imaging
(DWMRI) is sensitive to tissues’ biophysical character-
istics, including apparent diffusion coefficients (ADCs)
and volume fractions of water in different populations.
In this work, we evaluate the clinical efficacy of DWMRI
and high diffusion-weighted magnetic resonance
imaging (HDWMRI), acquired up to b = 4000 sec/mm2
to amplify sensitivity to water diffusion properties, in
pretreatment prediction of brain tumors’ response to
radiotherapy. Twelve patients with 20 brain lesions
were studied. Six ring-enhancing lesions were ex-
cluded due to their distinct diffusion characteristics.
Conventional and DWMRI were acquired on a 0.5-T
MRI. Response to therapy was determined from
relative changes in tumor volumes calculated from
contrast-enhanced T1-weighted MRI, acquired before
and a mean of 46 days after beginning therapy. ADCs
and a diffusion index, RD, reflecting tissue viability
based on water diffusion were calculated from
DWMRIs. Pretreatment values of ADC and RD were
found to correlate significantly with later tumor
response/nonresponse (r = 0.76, P < .002 and
r = 0.77, P < .001). This correlation implies that
tumors with low pretreatment diffusion values, indi-
cating high viability, will respond better to radio-
therapy than tumors with high diffusion values,
indicating necrosis. These results demonstrate the
feasibility of using DWMRI for pretreatment predic-
tion of response to therapy in patients with brain
tumors undergoing radiotherapy.
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Introduction
Diffusion-weighted magnetic resonance imaging (DWMRI)
enables noninvasive characterization of biological tissues
based on their water diffusion properties. It is widely accepted
that water in biological tissues is described in terms of a fast
equilibration between two main components [1,2], a population
of low-mobility/slow-diffusing water molecules (either bound to
macromolecules or confined within the cell membrane), and a
population of high-mobility water molecules, which is mostly
extracellular. It has been shown in vitro that the diffusion of
water molecules in the intracellular compartment is an order of
magnitude smaller than in the extracellular space. The acquisi-
tion of high diffusion-weighted magnetic resonance imaging
(HDWMRI), up to b = 4000 sec/mm2 in our case, amplifies the
sensitivity to water diffusion properties and enables the sepa-
ration of signals arising from the two populations [3,4]. Hence,
DWMRI should be sensitive to several physiological and mor-
phological characteristics of the tissues, which are associated
with the diffusion of the low- and high-mobilitywater populations.
Previous studies in animal models [5–7] and human brain
tumors [8,9] have demonstrated the ability of DWMRI to
distinguish solid viable tumors from cystic and necrotic regions
and have shown that water diffusion in tumors is correlated with
tumor cellularity [10–13]. Several studies investigating DWMRI
in tumors following various antitumor therapies [13–25] have
found increased apparent diffusion coefficients (ADCs) of
water that significantly preceded later tumor regression or
decelerated growth, thus enabling early detection of tumor
response. Most of these studies have used conventional
DWMRI, up to a b-value of about 1000 sec/mm2.
Several MR methods have been suggested recently as
having potential to predict tumor response to treatment. Con-
trast-enhanced MRI has been shown to be able to reveal
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distinct tumor patterns that can serve as a predictor
of response to chemotherapy in human breast cancer [26].
P-31 MR spectroscopy was shown in a preliminary study to
be a feasible method in predicting the response of head
and neck cancers to radiation therapy [27]. This method,
however, has a low sensitivity and is generally limited to large
and preferably superficial tumors. Recent diffusion-weighted
MR studies suggested that the initial ADC can serve as a
predictive parameter for chemosensitivity of primary rat
mammary tumors [7] and for chemoradiation/chemotherapy
response [28,29] in patients with rectal cancer.
Our group has previously shown that the capacity of
HDWMRI to obtain more information on the low-mobility
water population enhances the sensitivity, especially at early
stages, to relatively small treatment effects [30]. In a follow-
ing study, we demonstrated the application of HDWMRI for
pretreatment prediction of treatment outcome in an animal
model [31] (Roth et al., Pretreatment Prediction and Early
Monitoring of Tumor Response to Therapy Using High
b-Value Diffusion-Weighted MRI, submitted for publication).
In this work, we studied the correlation between pre-
treatment water diffusion characteristics and later tumor
response to treatment in patients with brain tumors under-
going radiation therapy. The results suggest that diffusion
characteristics, related to the overall viability of the tumor,
may be used for noninvasive prediction of treatment out-
come prior to initiation of treatment.
Materials and Methods
Patients and Treatment
Twelve patients with 20 brain lesions were studied. Three
patients had gliomas (grades III and IV) and nine patients
had brain metastasis (six breast cancers, two lung cancers,
and one prostate cancer). All patients received standard
fractionated radiation therapy. The high-grade glioma
patients received fractions of 2 Gy/day for a total of 54 to
60 Gy. The patients with metastases received either
3 Gy/day for a total of 30 Gy, or 2 Gy/day for a total of
40 Gy. All patients underwent MR scans before treatment
and at regular intervals thereafter.
Equipment and Software
Data were acquired on a General Electric (Waukesha,
WI) 0.5-T interventional MRI machine [Signa SP/i (special
proceeding/interventional)] at the Chaim Sheba Medical
Center using the Line Scan DWMRI (LSDI [32]) software.
The standard GE head coil was used for data acquisition.
Image analysis was performed using the Interactive Data
Language (IDL), version 3.6.1, of Research Systems Inc.
(Berkshire, UK) and InStat GraphPad (San Diego, CA)
version 3.05 software packages.
Diffusion-Weighted MR Method
Diffusion-weighted images are usually obtained by ac-
quiring conventional T2-weighted images with the addition of
diffusion-weighting gradients that filter out the signal from
high-mobility water molecules and sensitize the MR images
to molecular diffusion/mobility [33]. Hence, regions of accu-
mulated liquids or severe necrosis appear dark in DWMRI.
At low diffusion-weighting values, most of the signals from
the tissues are present in the images. At high diffusion-
weighting values, most of the signals are filtered out, and
the signal remaining in the image originates mostly from low-
mobility molecules.
In this method, the normalized intensity of the water signal
is given by:
ð1Þ I=I0 ¼ exp½bADC ð1Þ
where I and I0 denote the signal intensities in the presence
and absence of diffusion-weighting gradients, ADC is the
molecular ADC, and b is the diffusion weighting factor, which
is expressed in units of seconds per square millimeter.
By varying b (i.e., varying the intensity, duration, and/or
separation time of the gradients), a diffusion curve can be
obtained in which ln(I/I0) is plotted as a function of b
(Figure 1).
In order to quantify the diffusion characteristics of the
tissue as reflected in the diffusion curve, we define a diffusion
index, RD, which is the normalized summation over the
curve:
ð2Þ RD ¼ 
Xm
j¼0
ln
Ij
I0
 
ð2Þ
The summation is over m data points of the diffusion curve.
The division by I0 reduces the T2 effect. Therefore, small RD
indicates slow signal decay as a function of b, implying more
viable tissue. Regions with high RD correspond to more
necrotic tissues.
Data Acquisition
Line scan DW images, gadolinium contrast-enhanced
spin-echo T1-weighted MR images, and fast spin-echo
T2-weighted MR images were used to monitor the patients
before and at regular intervals following treatment. All
images were acquired with 5-mm slices, two signal aver-
ages, and a 2216.5-cm field of view. T2-weighted MR
images were acquired with a 256128 matrix, TR = 3000
milliseconds, and TE = 19/95 milliseconds. T1-weighted MR
images were acquired with a 256128 matrix, TR = 500
Figure 1. Mean signal intensity as a function of the diffusion factor b, for
necrotic tissue, viable tissue, and noise level.
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milliseconds, and TE = 14.5 milliseconds. DWMR images
were acquired with a 12864 matrix, b = 5 and
1000 sec/mm2, d = 31 milliseconds, D = 51 milliseconds,
TR = 2907 milliseconds, and TE = 105.2 milliseconds. Diffu-
sion curves were calculated from additional DWMR images
acquired at 14 b -values ranging from 15 to 4000 sec/mm2,
d = 53 milliseconds, D = 73 milliseconds, TR = 4964 milli-
seconds, TE = 149.8 milliseconds, and one signal average.
In normal white matter, the diffusion of the water molecules
is anisotropic and data must be acquired in at least three
orthogonal directions and then averaged in order to obtain
isotropic diffusion coefficients. In this work, datawere acquired
using a monodirectional diffusion scheme (described in detail
in Ref. [32]) with all three gradients turned on at the same time,
due to long acquisition times at 0.5 T. This measurement
should suffice due to the natural isotropy of cancer tumors and
the reasonably reproducible head orientation.
The duration of a conventional DWMRI measurement at
b = 5 and 1000 sec/mm2 was 20 seconds per average per
slice. In this study, we used two averages; therefore, the scan
lasted 40 seconds per slice. The number of slices varied from
patient to patient, chosen in a manner that covered the entire
tumor with an extra slice in each direction. The duration of a
14 b-value scan was 3 minutes and 47 seconds per slice. In
order to save scan time, only three to four slices, chosen in
the center of the tumor, were scanned. The overall diffusion
scan time was, therefore, of the order of 20 minutes. In
addition, precontrast and postcontrast T1-weighted and
T2-weighted images were acquired. Thus, the overall scan
time of an average exam reached 40 to 50 minutes.
Assessment of Tumor Response
Tumor volumes were calculated from the contrast-
enhanced T1-weighted images. A region of interest (ROI)
was defined over the entire apparent tumor in each slice and
the number of pixels was counted. Tumor volumes in cubic
centimeters were calculated prior to treatment and 46 days,
on average, posttreatment. The relative change in tumor
volume was defined as the ratio between the final volume
and the initial volume.
Responding tumors were defined as tumors that de-
creased to 50% or less of their original volume. The rest
were defined as stable/nonresponding tumors.
Analysis of DWMRI Data
ADCs were calculated on a pixel-by-pixel basis using the
LSDI images acquired at b = 5 and 1000 sec/mm2 (Eq. (1)) to
form ADCmaps. Examples are shown in Figures 2D and 3D.
Diffusion curves were obtained by plotting the logarithmic
signal intensity in the diffusion-weighted image (I ) normal-
ized to the signal intensity of the image acquired at
b = 15 mm2/sec (I0), as a function of b (Eq. (2)), on a pixel-
by-pixel basis. RD was then calculated by summing over the
14 images in the curve to form RD maps (Figures 2C and
3C). ROIs were defined over the entire apparent tumor in the
contrast-enhanced T1-weighted images and copied to the
diffusion maps. Mean ADC and RD values were calculated
for each tumor. Error bars were defined as the standard
deviations of ROIs chosen in the contralateral normal tissue.
The diffusion parameters were then correlated with re-
sponse/nonresponse, as determined by the relative change
in tumor volume measured, on average, 46 days after
initiation of treatment. The error bars were incorporated in
the calculation of the correlation parameters.
Results
Ring Enhancement Lesions
Six lesions (five lung cancer metastases and one breast
cancer metastasis) were defined as ring enhancement
lesions (Table 1). They all appeared on T1-weighted MRI
as cystic lesions surrounded by a thin enhancing rim. An
example is shown in Figure 4. The ADC values of these
lesions were significantly higher than all other lesions (Mann-
Whitney, two tail, P < .0001) and they responded well to
therapy. There was a clear correlation between the volume of
the lesions and their mean ADC values, up to a value of
2.4103 mm2/sec, where it plateaus (Figure 5). These
lesions were not included in the study.
Pretreatment Prediction of Response
The tumors included in the study covered a wide range
of tissue viability [RD: 14.4–25.4; ADC: (0.7–1.3)103
mm2/sec] and in tumor response (0.08–1.42). The pretreat-
ment values of the diffusion parameters, ADC and RD, as
well as the relative changes in tumor volumes 46 days, on
average, after initiation of treatment are listed in Table 2 for
all 14 tumors.
Viable tissues are associated with low water mobility;
therefore, viable tumors appear dark on ADC and RD maps,
Figure 2. Axial images of a patient with breast cancer metastasis tumor
(arrow). The tumor appears dark in the diffusions maps, suggesting viable
tissue. (A) Contrast-enhanced T1-weighted image; (B) T2-weighted image;
(C) RD map; and (D) ADC map.
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whereas necrotic tumors appear bright. Example of diffusion
maps of tumors with different water diffusion characteristics
are shown in Figures 2 and 3.
The potential of using pretreatment diffusion character-
istics to predict tumor response to therapy was studied by
correlating the tumor diffusion parameters, ADC and RD
(reflecting tissue viability), measured prior to initiation of
treatment, with the relative change in tumor volume, mea-
sured, on average, 46 days after initiation of treatment.
The positive correlation between pretreatment values of
ADC and later tumor response is considered very significant
(P < .002, r = 0.76, Pearson correlation), as presented in
Figure 6.
The positive correlation between pretreatment values of
RD (calculated from HDWMRI) and later tumor response is
considered very significant (P < .001, r = 0.77, Pearson
correlation), as presented in Figure 7.
In order to determine the contribution of the high b-value
data to the prediction of response,RD was recalculated using
b-values up to 940 sec/mm2 (conventional values). The
positive correlation between the pretreatment values of this
parameter and later tumor response is similar to the corre-
lation found for the ADC (P < .002, r = 0.76, Pearson
correlation).
A comparison between the diffusion parameters of
responding and stable/nonresponding tumors using a two-
tailed P value Mann-Whitney test resulted in P < .0007
for both RD and ADC, which is considered extremely signif-
icant. The 95% confidence ranges were 14.1 to 18.5
(responding) and 20.5 to 24.4 (stable/nonresponding) for
RD and (0.7 – 0.9)103 mm2/sec (responding) and
(1.1–1.3)103 mm2/sec (stable/nonresponding) for ADC.
The positive correlation between the pretreatment val-
ues of the two diffusion parameters (ADC and RD) is
considered extremely significant (P < .0001, r = 0.95, Pear-
son correlation).
Discussion
The metastases defined as ring enhancement lesions were
not includedin thestudy.Theiruniqueradiologicalappearance
Table 1. Diffusion and Volume Parameters of the Six Ring Enhancement
Tumors Not Included in the Study.
Lesion
Number
Tumor
Type
Initial Tumor
Volume (mm2)
ADC103
(mm2/sec)
(b = 1000 sec/mm2)
Relative Change
in Tumor Volume
1 Lung 6983 2.2 0.7
2 Lung 2635 2.4 0.4
3 Lung 1079 2.4 0.3
4 Lung 250 1.4 0
5 Lung 356 1.9 0
6 Breast 330 1.7 0.7
ADC values were calculated from images acquired at b = 5 and 1000 sec/
mm2. Volumes were calculated from contrast-enhanced T1-weighted images.
Figure 3. Axial images of a patient with a GBM (arrow). The tumor appears
bright in the diffusions maps, suggesting necrotic tissue. (A) Contrast-
enhanced T1-weighted image; (B) T2-weighted image; (C) RD map; and (D)
ADC map.
Figure 4. Axial images of a patient with small cell lung cancer metastasis.
The tumor is defined as a ring enhancement tumor. (A) Contrast-enhanced
T1-weighted image; (B) T2-weighted image; (C) RD map; and (D) ADC map.
Figure 5. Plot of pretreatment mean ADC values as a function of lesion
volume for ring enhancement tumors. There is a clear correlation up to a
value of 2.4103 mm2/sec, where the ADC value plateaus.
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and high response to treatment are consistent with previous
studies [26]. These lesions had no massive tumor but the
enhancing rim surrounding the cystic content. Because the
partial volume of the viable rim decreases as the total lesion
volume increases, it is reasonable to assume that their
diffusion characteristics are dominated by their volumes.
This effect is reflected in the correlation observed between
the lesion volume and the ADC value. Therefore, the diffu-
sion characteristics of these lesions do not reflect their
overall viability; thus, they were not included in the study.
The tumors included in the study are spread over a wide
range of tissue viabilities and tumor responses, enabling us
to study the correlation between pretreatment values of the
diffusion parameters and treatment outcomes over a wide
range of lesions.
Previous studies have shown that regions appearing dark
in DWMR images are associated with more necrotic tissues
[10–13,15,23]. Hence, high ADC values and diffusion curves
that decay quickly with b (high RD values) are typical of low
cellularity and necrotic tissues, whereas low ADC values and
curves that decay slowly with b (low RD values) may indicate
more viable tissues with higher cellularity. Therefore, the
mean ADC and RD values calculated for each tumor (by
choosing ROIs over the entire tumor and averaging over
these ROIs) reflect tumor cellularity/viability. The positive
correlation between the values of the pretreatment diffusion
parameters and later response/nonresponse to therapy
implies that cellular/viable tumors respond better to radiation
therapy than necrotic tumors.
A possible explanation may be related to the fact that the
viable cancer cells adjacent to necrotic regions may experi-
ence hypoxic conditions and therefore may be less sensitive
to radiation therapy [34,35].
To the best knowledge of the authors, the only published
clinical studies [28,29] that show a correlation between
pretreatment ADCs and response to therapy consist of
patients with rectal carcinoma treated with chemoradiation.
The correlations presented in these papers are consistent
with the data presented in our study with brain tumors in the
sense that low ADC tumors respond better to treatment than
high ADC tumors.
In two recent studies [30,31] we have demonstrated
the additional sensitivity gained by using high b-value
Figure 6. Plot of tumor pretreatment mean ADC values as a function of the
relative change in tumor volume (ratio between final volume and initial
volume) 46 days, on average, after initiation of treatment. The significant
correlation demonstrates the potential of this method for pretreatment
prediction of response to therapy.
Table 2. Diffusion and Volume Parameters of the 14 Brain Tumors Included the Study.
Lesion Number Tumor Type ADC  103 (mm2/sec)
(b = 1000 sec/mm2)
RD Relative Change
in Tumor Volume
Time of
Measurement of
Volume Change
1 GBM 1.06 ± 0.09 20.0 ± 1.6 1.0 40
2 Breast 0.69 ± 0.05 14.4 ± 1.5 2.4 44
3 Breast 0.79 ± 0.08 15.7 ± 1.3 0.4 44
4 Glioma III 1.08 ± 0.08 21.7 ± 0.9 1.3 54
5 Glioma III 1.17 ± 0.05 25.0 ± 0.9 1.1 50
6 Breast 0.73 ± 0.13 15.2 ± 2.3 0.4 47
7 Prostate 0.78 ± 0.07 14.7 ± 0.8 1.4 54
8 Breast 1.08 ± 0.06 20.1 ± 1.3 0.6 51
9 Breast 1.33 ± 0.08 25.4 ± 1.6 0.8 51
10 Breast 1.24 ± 0.08 24.9 ± 2.5 1.4 51
11 Breast 1.19 ± 0.11 20.5 ± 2.0 1.0 51
12 Breast 0.99 ± 0.07 19.8 ± 1.6 0.5 30
13 Breast 1.24 ± 0.06 21.9 ± 1.4 0.9 30
14 Breast 0.92 ± 0.07 17.8 ± 1.4 0.1 52
ADC values were calculated from images acquired at b = 5 and 1000 sec/mm2. RD values were calculated from images acquired at 14 b-values ranging from b = 15
to 4000 sec/mm2. The relative change in tumor volume was defined as the ratio between the final tumor volume (measured 46 days, on average, after treatment
initiation) and the pretreatment volume as determined from contrast-enhanced T1-weighted MR images.
Figure 7. Plot of tumors pretreatment mean RD values as a function of the
relative change in tumor volume (ratio between final volume and initial
volume) 46 days, on average, after initiation of treatment. The significant
correlation demonstrates the potential of this method for pretreatment
prediction of response to therapy.
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DWMRI, both for pretreatment prediction of response
to therapy (animal study and chemotherapy) and for
early posttreatment detection of response to therapy
(clinical study, brain tumors, and radiosurgery/radiation
therapy).
The current study demonstrates a similar predictive pow-
er for the parameters calculated from conventional and high
b-value data. The high correlation between the ADC values
and the RD values suggests that in this case, most of the
information is contained already in the ADC data (i.e., in the
conventional DWMRIs). Further studies on higher-field MR
systems should be carried out in order to determine the value
of HDWMRI in the pretreatment prediction of response to
therapy.
This study was performed using a relatively low magnetic
field of 0.5 T and relatively weak diffusion gradients of
1 G/cm. The data were acquired using the LSDI sequence.
Although this approach is less sensitive to motion and
susceptibility artifacts, it yields relatively low signal-to-noise
data per unit scan time and requires longer scan times. This
combination results in low signal-to-noise ratio (SNR), espe-
cially in the high diffusion-weighted data. In order to com-
pensate for the low SNR, we acquired a large number [14]
of b-values, resulting in better SNR for the calculated diffu-
sion index (Eq. (2)) but relatively long scan times. In addition,
we defined a diffusion index,RD, calculated by summing over
the normalized signal intensities of the diffusion curves. In
a previous publication [30], we have used a similar diffusion
index, R, calculated from the ADCs and volume fractions
of the two water populations, obtained by fitting the HDWMRI
data to a biexponential function. In the current study,
R and RD were found to be highly correlated, but due to
the higher sensitivity of R to low SNR, the predictive power of
RD was greater (data not shown). Once using a higher field
magnet with better SNR, Rmay become advantageous over
RD due to the separation of the two water components
(obtained using the biexponential fit) and because it is
protocol-independent.
With single-shot diffusion-weighted echo-planar imaging
(EPI) [36], which is available on most new MR machines,
data of several slices could be obtained without increasing
scan times. This type of sequence would be more appropri-
ate for routine clinical use rather than the methodology
presented here due to its availability and short acquisition
times, although some susceptibility artifacts may be formed
in boundary areas. A combination of short scan times and
reduced sensitivity to susceptibility variations is offered by
novel diffusion imaging techniques, such as slab scan diffu-
sion imaging [37] or single-shot EPI with sensitivity-encoded
single shot (SENSE) [38].
In summary, this study demonstrates the feasibility of
using conventional and high b-value DWMRI as a noninva-
sive tool for pretreatment prediction of response to radiation
therapy in patients with malignant brain tumors. We are
currently extending this study to higher magnetic fields and
stronger gradient intensities in order to establish the appli-
cation of this method for clinical use, thus enabling optimi-
zation of the management of malignancy.
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